MedTrace Logo

Vitamin D Deficiency, Insulin Resistance and FGF-23

NCT00491322 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2018-05-02

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to determine if treating vitamin D deficiency decreases insulin resistance and improves insulin secretion in healthy volunteers. Additionally, this project will investigate if treating vitamin D deficiency affects a new phosphate-regulating hormone called FGF-23.

Conditions

  • Vitamin D Deficiency

Interventions

DIETARY_SUPPLEMENT

Ergocalciferol

Ergocalciferol 50000 international units once a week for 12 weeks

DIETARY_SUPPLEMENT

Ergocalciferol placebo

Ergocalciferol placebo once a week for 12 weeks

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Sherri-Ann M Burnett-Bowie, MD, MPH · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00491322 on ClinicalTrials.gov